Clinical Data Novo Nordisk data shows oral semaglutide delivers significant weight loss in phase 3 trial PharmaTimesResponders achieved weight loss and improvements in physical functionMetabolic & GLP-1Read full story pharminent May 13, 2026 (Last updated: May 21, 2026) PharmaTimes Responders achieved weight loss and improvements in physical function Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: UAE approves AstraZeneca’s Baxfendy for hypertensionNext: Clock starts ticking on UK’s single patient record plan Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
